Clinical Trials Browser

Combined Modality Therapy × Thoracic × Clear all

Mesothelioma, Malignant

NCT03556228 2025-12-11

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

GastrointestinalHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Adenoid Cystic, Esophageal Neoplasms, Head and Neck Neoplasms, Laryngeal Diseases, Lung Neoplasms, Mesothelioma, Neoplasm Metastasis, Pancreatic Neoplasms, Salivary Gland Neoplasms, Tracheal Diseases, Small Cell Lung Carcinoma

NCT04846452 2021-08-12

Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC

Phase 2 Unknown

40 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04942301 2021-06-30

PK Study for Endostar Continuous Intravenous Infusion in NSCLC Patients With 1st-line Platinum Based Chemotherapy

Phase 1 Unknown

24 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

SW-682 in Advanced Solid Tumors

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC

PK Study for Endostar Continuous Intravenous Infusion in NSCLC Patients With 1st-line Platinum Based Chemotherapy